Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Amgen's Cancer Strategy: A Multitude Of Modalities In Immuno-Oncology And Beyond

Executive Summary

Amgen is the leader in approved bispecific antibodies and oncolytic viruses, but the company's not shy about expanding its oncology pipeline with even more modes of delivering medicines to cancer patients.

You may also be interested in...



Advaxis Stumbles Further As Amgen Exits Early-Stage Cancer Immunotherapy Pact

Troubled by a clinical hold for another program, Advaxis now regains all rights to ADXS-NEO, a personalized immunotherapy in Phase I for cervical and head-and-neck cancers.

Amgen Focuses On Pipeline As Mature Products Face Declining Demand

Amgen ended its own development of the CETP inhibitor AMG 899, but will see if anyone else wants to license the drug. Meanwhile, the company is focusing on new drugs and assets in development to offset declining sales for Enbrel and other blockbusters.

Deal Watch: J.P. Morgan Brings Continued Brisk Pace Of Transactions

Allergan strikes a pair of deals for gastrointestinal and CNS candidates, while Amgen expands its reach in bispecific antibodies via a partnership with Immatics.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC097199

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel